The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell ...
MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.
The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...
Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...
Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...
Kidney cancer is a disease where cancer cells begin to develop abnormally in the kidneys. As cancer cells grow rapidly, they can form a tumor, and eventually, the cancer can spread to other parts of ...
Add Yahoo as a preferred source to see more of our stories on Google. On the list of medical terms we’d rather never hear, cancer is at the top. But when it comes to fighting it, knowledge is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results